Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Alkermes plc Reports Second Quarter 2021 Financial Results

      This image opens in the lightbox

      News provided by

      Alkermes plc

      28 Jul, 2021, 11:00 GMT

      Share this article

      Share this article


      —    Second Quarter Revenues of $303.7 Million Reflect 23% Growth Year-Over-Year —

      —    Diluted GAAP Earnings per Share of $0.01 and Diluted Non-GAAP Earnings per Share of $0.30, Driven by Operational Execution —

      —    Company Updates Full-Year 2021 Financial Expectations Based on Strong First Half Performance  —

      DUBLIN, July 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2021 and provided updated financial expectations for full-year 2021.

      "Alkermes' strong performance in the second quarter was driven by commercial execution and our focus on profitability. VIVITROL® and ARISTADA® demonstrated robust sequential and year-over-year growth and VUMERITY® continued on an encouraging launch trajectory," commented Iain Brown, Chief Financial Officer of Alkermes. "Today, we are raising our financial expectations for full-year 2021 to reflect this performance and anticipated continued strength in the business. We believe that we are in a sound financial position to execute on our business strategy and efficiently invest in our future potential growth drivers."

      Quarter Ended June 30, 2021 Financial Results

      Revenues

      • Total revenues for the quarter were $303.7 million. This compared to $247.5 million for the same period in the prior year.
      • Net sales of proprietary products for the quarter were $160.8 million, compared to $130.4 million for the same period in the prior year.
        • Net sales of VIVITROL were $88.4 million, compared to $71.6 million for the same period in the prior year, representing an increase of approximately 23%.
        • Net sales of ARISTADAi were $72.4 million, compared to $58.8 million for the same period in the prior year, representing an increase of approximately 23%.
      • Manufacturing and royalty revenues for the quarter were $142.3 million, compared to $116.5 million for the same period in the prior year.
        • Manufacturing and royalty revenues from RISPERDAL CONSTA®, INVEGA SUSTENNA®/XEPLION® and INVEGA TRINZA®/TREVICTA® were $95.5 million, compared to $83.1 million for the same period in the prior year.
        • Manufacturing and royalty revenues from VUMERITY® were $20.3 million, compared to $2.6 million for the same period in the prior year.

      Costs and Expenses

      • Total operating expenses for the quarter were $299.3 million, compared to $281.2 million for the same period in the prior year.
        • Cost of Goods Manufactured and Sold were $53.1 million, compared to $45.1 million for the same period in the prior year.
        • Research and Development (R&D) expenses were $97.5 million, compared to $94.2 million for the same period in the prior year.
        • Selling, General and Administrative (SG&A) expenses were $139.2 million, compared to $132.0 million for the same period in the prior year.

      Profitability

      • Net income according to generally accepted accounting principles in the U.S. (GAAP) was $2.4 million for the quarter, or a basic and diluted GAAP earnings per share of $0.01. This compared to GAAP net loss of $29.4 million, or a basic and diluted GAAP loss per share of $0.19, for the same period in the prior year.
      • Non-GAAP net income was $49.2 million for the quarter, or a non-GAAP basic earnings per share of $0.31 and a non-GAAP diluted earnings per share of $0.30. This compared to non-GAAP net income of $8.9 million, or a non-GAAP basic and diluted earnings per share of $0.06 for the same period in the prior year.

      Balance Sheet

      • At June 30, 2021, the company recorded cash, cash equivalents and total investments of $669.4 million, compared to $627.4 million at March 31, 2021, driven primarily by the company's operating results and changes in working capital. The company's total debt outstanding as of June 30, 2021 was $297.1 million.

      Financial Expectations for 2021

      The following financial expectations for 2021 are based on recent trends and assume continued improvement in patient access to treatment providers and to the company's commercial products in the second half of the year. If patient access does not improve as anticipated, or if new COVID-19-related disruptions emerge, the company's ability to meet these expectations could be negatively impacted. All line items are according to GAAP, except as otherwise noted.

      In millions (except per share amounts)


      Current 2021 Expectation

      (Provided 7/28/21)

      Prior 2021

      Expectation

      (Provided 2/11/21)





      Total Revenue


      $1,145 – $1,185

      $1,100 – $1,170

      VIVITROL Net Sales


      $330 – $345

      $315 – $345

      ARISTADA Net Sales


      $275 – $290

      $260 – $290

      LYBALVI® Net Sales


      <$10

      <$10

      Cost of Goods Sold


      $195 – $205

      $190 – $200

      R&D Expenses


      $400 – $430*

      $400 – $430*

      SG&A Expenses


      $560 – $590

      $570 – $600

      Amortization of Intangible Assets


      ~$40

      ~$40

      Other Expense, Net


      $0 – $5

      $0

      Income Tax Expense


      $5 – $10

      $0 – $10

      GAAP Net Loss


      ($60) – ($90)

      ($85) – ($125)

      GAAP Net Loss per Share+


      ($0.37) – ($0.56)

      ($0.53) – ($0.78)

      Non-GAAP Net Income


      $85 – $115

      $60 – $100

      Non-GAAP Diluted EPS+


      $0.52 – $0.70

      $0.37 – $0.62

      Capital Expenditures


      ~$35

      ~$40

      *R&D expense expectations for 2021 include an anticipated $25 million milestone payment in the third quarter to the former shareholders of Rodin Therapeutics, Inc. related to the expected submission of an investigational new drug application, or equivalent, for ALKS 1140, the first clinical candidate to emerge from the histone deacetylase (HDAC) inhibitor platform acquired by the company in late 2019.

      + The current 2021 per share expectations are calculated based on a weighted average basic share count of approximately 161 million shares outstanding and a weighted average diluted share count of approximately 164 million shares outstanding, as compared to prior expectations of approximately 160 million and 161 million, respectively.

      "Our achievements in the second quarter demonstrated continued execution against our strategic priorities. Our strong commercial performance, the FDA approval of LYBALVI and the accumulating data and operational progress in our nemvaleukin immuno-oncology program represent important milestones for the company and provide a meaningful platform to drive future growth," said Richard Pops, Chief Executive Officer of Alkermes. "Guided by our intense focus on value creation, our objectives for the remainder of 2021 are clear: successfully launch LYBALVI; drive the growth of VIVITROL and ARISTADA; advance the clinical development program for nemvaleukin; and invest in our emerging neuroscience and oncology pipeline assets."

      Recent Events:

      Psychiatry

      • In June 2021, the company announced FDA approval of LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproateii. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, co-formulated with samidorphan, a new chemical entity, in a single bilayer tablet.

      Nemvaleukin alfa ("nemvaleukin")

      • In June 2021, the company presented updated data from the ARTISTRY clinical development program for nemvaleukin, the company's novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting. In conjunction with the data presentation at ASCO, the company hosted an investor webcast with ARTISTRY clinical program investigators Valentina Boni, M.D., Ph.D., Medical Oncologist and Principal Investigator at START Madrid at Centro Integral Oncológico Clara Campal and Omid Hamid, M.D., Chief of Research and Immunotherapy at The Angeles Clinic and Research Institute.

      Corporate

      • In May 2021, the company announced the appointment of Emily Peterson Alva to the company's Board of Directors (the Board). Ms. Alva is an experienced public company board member and a financial, strategic and business advisor to growth companies. Ms. Alva is the fifth new, independent director to join the Board in the past two years.
      • In July 2021, the company awarded grants from its Alkermes Inspiration Grants® program to 11 nonprofit organizations working to address the needs of people living with addiction, serious mental illness or cancer.

      Conference Call
      Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 28, 2021, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.

      About Alkermes plc
      Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

      Non-GAAP Financial Measures
      This press release includes information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

      Non-GAAP net income (loss) adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; certain other one-time or non-cash items; and the income tax effect of these reconciling items.

      The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share should not be considered measures of the company's liquidity.

      A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

      Note Regarding Forward-Looking Statements
      Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning future financial and operating performance, business plans or prospects, including the expected drivers of future growth and value creation; expectations of continued improvement in patient access to healthcare providers and to the company's commercial products; the potential therapeutic and commercial value of the company's marketed and development products; expectations concerning the company's future development activities, including plans for submission of an investigational new drug application or equivalent for ALKS 1140, advancement of the clinical development program for nemvaleukin and further investment in the company's neuroscience and oncology development pipeline; and expectations concerning the company's commercial activities, including the anticipated launch of LYBALVI. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the company may not be able to achieve its targeted financial and profitability metrics in a timely manner or at all; the impacts of the ongoing COVID-19 pandemic and continued efforts to mitigate its spread on the company's business, results of operations or financial condition, including impacts on healthcare systems and patient and healthcare provider access to the company's commercial products and impacts on the regulatory agencies with which the company interacts in the development, review, approval and commercialization of its medicines; the unfavorable outcome of litigation, including so-called "Paragraph IV" litigation and other patent litigation, or other disputes related to our products or products using our proprietary technologies; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and the adequacy of the data and other information included in our submissions to support the FDA's requirements for approval; regulatory submissions may not occur or be submitted in a timely manner; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2020 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission ("SEC"), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

      VIVITROL® is a registered trademark, and ALKERMES INSPIRATION GRANTS® is a registered service mark, of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited; RISPERDAL CONSTA®, INVEGA SUSTENNA®, XEPLION®, INVEGA TRINZA® and TREVICTA® are registered trademarks of Johnson & Johnson; and VUMERITY® is a registered trademark of Biogen Inc., used by Alkermes under license.

       (tables follow)

      Alkermes plc and Subsidiaries

      Selected Financial Information (Unaudited)






      Condensed Consolidated Statements of Operations - GAAP


      Three Months Ended 


      Three Months Ended 

      (In thousands, except per share data)


      June 30, 2021


      June 30, 2020

      Revenues:





      Product sales, net


      $                  160,808


      $                  130,415

      Manufacturing and royalty revenues


      142,294


      116,505

      Research and development revenue


      615


      609

      Total Revenues


      303,717


      247,529

      Expenses:





      Cost of goods manufactured and sold


      53,124


      45,053

      Research and development


      97,473


      94,222

      Selling, general and administrative


      139,188


      132,025

      Amortization of acquired intangible assets


      9,511


      9,890

      Total Expenses


      299,296


      281,190

      Operating Income (Loss)


      4,421


      (33,661)

      Other Income, net:





      Interest income


      623


      1,788

      Interest expense


      (2,407)


      (2,122)

      Change in the fair value of contingent consideration


      3,240


      5,900

      Other (expense) income, net


      (222)


      2,337

      Total Other Income, net


      1,234


      7,903

      Income (Loss) Before Income Taxes


      5,655


      (25,758)

      Provision for Income Taxes


      3,291


      3,673

      Net Income (Loss) — GAAP


      $                      2,364


      $                  (29,431)






      Earnings (Loss) Per Share:





      GAAP earnings (loss) per share — basic and diluted


      $                        0.01


      $                      (0.19)

      Non-GAAP earnings per share — basic


      $                        0.31


      $                        0.06

      Non-GAAP earnings per share — diluted


      $                        0.30


      $                        0.06






      Weighted Average Number of Ordinary Shares Outstanding:





      Basic — GAAP


      160,817


      158,895

      Diluted — GAAP 


      163,937


      158,895

      Basic — Non-GAAP


      160,817


      158,895

      Diluted — Non-GAAP


      163,937


      159,275






      An itemized reconciliation between net income (loss) on a GAAP basis and non-GAAP net income is as follows:

      Net Income (Loss) — GAAP


      $                      2,364


      $                  (29,431)

      Adjustments:





      Share-based compensation expense


      27,552


      22,846

      Depreciation expense


      8,966


      10,447

      Amortization expense


      9,511


      9,890

      Income tax effect related to reconciling items


      3,927


      877

      Non-cash net interest expense


      117


      167

      Change in the fair value of contingent consideration


      (3,240)


      (5,900)

      Non-GAAP Net Income


      $                    49,197


      $                      8,896





















      Condensed Consolidated Statements of Operations - GAAP


      Six Months Ended 


      Six Months Ended 

      (In thousands, except per share data)


      June 30, 2021


      June 30, 2020

      Revenues:





      Product sales, net


      $                  290,771


      $                  260,141

      Manufacturing and royalty revenues


      262,141


      232,756

      License revenue


      1,500


      —

      Research and development revenue


      735


      852

      Total Revenues


      555,147


      493,749

      Expenses:





      Cost of goods manufactured and sold


      94,144


      92,264

      Research and development


      189,741


      187,501

      Selling, general and administrative


      264,356


      265,397

      Amortization of acquired intangible assets


      18,917


      19,618

      Total Expenses


      567,158


      564,780

      Operating Loss


      (12,011)


      (71,031)

      Other (Expense) Income, net:





        Interest income


      1,487


      4,548

        Interest expense


      (6,377)


      (4,979)

        Change in the fair value of contingent consideration


      4,518


      12,700

        Other (expense) income, net


      (615)


      1,679

      Total Other (Expense) Income, net


      (987)


      13,948

      Loss Before Income Taxes


      (12,998)


      (57,083)

      Provision for Income Taxes


      7,056


      11,002

      Net Loss — GAAP


      $                  (20,054)


      $                  (68,085)






      (Loss) Earnings Per Share:





      GAAP loss per share — basic and diluted


      $                      (0.13)


      $                      (0.43)

      Non-GAAP earnings per share — basic


      $                        0.42


      $                        0.07

      Non-GAAP earnings per share — diluted


      $                        0.41


      $                        0.07






      Weighted Average Number of Ordinary Shares Outstanding:





      Basic and diluted — GAAP


      160,229


      158,495

      Basic — Non-GAAP


      160,229


      158,495

      Diluted — Non-GAAP


      163,174


      159,151






      An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income is as follows:

      Net Loss — GAAP


      $                  (20,054)


      $                  (68,085)

      Adjustments:





      Share-based compensation expense


      43,003


      42,659

      Depreciation expense


      19,203


      21,328

      Amortization expense


      18,917


      19,618

      Income tax effect related to reconciling items


      8,106


      6,797

      Non-cash net interest expense


      235


      334

      Debt refinancing charge


      2,109


      —

      Change in the fair value of contingent consideration


      (4,518)


      (12,700)

      Acquisition of IPR&D


      —


      674

      Non-GAAP Net Income


      $                    67,001


      $                    10,625
















      Condensed Consolidated Balance Sheets


      June 30, 


      December 31, 

      (In thousands)


      2021


      2020

      Cash, cash equivalents and total investments


      $                  669,377


      $                  659,807

      Receivables


      297,357


      275,143

      Contract assets


      8,793


      14,401

      Inventory


      136,077


      125,738

      Prepaid expenses and other current assets


      57,186


      60,662

      Property, plant and equipment, net


      343,949


      350,003

      Intangible assets, net and goodwill


      186,147


      204,064

      Other assets


      238,683


      259,912

      Total Assets


      $               1,937,569


      $               1,949,730

      Long-term debt — current portion


      $                      3,000


      $                      2,843

      Other current liabilities


      380,442


      435,415

      Long-term debt   


      294,070


      272,118

      Contract liabilities — long-term 


      14,167


      16,397

      Other long-term liabilities


      147,988


      155,975

      Total shareholders' equity


      1,097,902


      1,066,982

      Total Liabilities and Shareholders' Equity


      $               1,937,569


      $               1,949,730






      Ordinary shares outstanding (in thousands)


      161,296


      159,161






      This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the three and six months ended June 30, 2021, which the company intends to file in July 2021.

      2021 Guidance — GAAP to Non-GAAP Adjustments








      An itemized reconciliation between projected loss per share on a GAAP basis and projected earnings per share on a non-GAAP basis is as follows:








      (In millions, except per share data)


      Amount


      Shares


      (Loss)
      Earnings
      Per
      Share

      Projected Net Loss — GAAP


      $                      (75.0)


      161


      $       (0.47)

         Adjustments:







      Share-based compensation expense


      90.0





      Depreciation expense


      42.0





      Amortization expense


      40.0





      Income tax effect related to reconciling items 


      5.0





      Other (expense) income, net


      2.0





      Non-cash net interest expense


      1.0





      Change in the fair value of contingent consideration


      (5.0)





      Projected Net Income — Non-GAAP


      $                      100.0


      164


      $        0.61








      Projected GAAP and non-GAAP measures reflect mid-points within ranges of estimated guidance.


      i The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise.
      ii Full prescribing information, including boxed warning, for LYBALVI may be found at www.lybalvi.com/lybalvi-prescribing-information.pdf

      Alkermes Contacts:



      For Investors:

      Sandy Coombs      

      +1 781 609 6377



      For Media:

      Katie Joyce  

      +1 781 249 8927

      Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.